Mononucleosis Diagnostic Market Size was valued at USD 1.7 Billion in 2023. The Mononucleosis Diagnostic Market industry is projected to grow from USD 1.8 Billion in 2024 to USD 3.28 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.60% during the forecast period (2024 - 2032). Increased health awareness and patient knowledge, coupled with advancements in technology enabling faster diagnosis and the expanding adolescent population, are expected to be significant market drivers for the Mononucleosis Diagnostic Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Rising incidences of infectious mononucleosis (IM) and the increasing adolescent population are driving the market growth.
Market CAGR for Mononucleosis Diagnostic is driven by the rising incidences of infectious mononucleosis (IM) and the increasing adolescent population. According to the Centers for Disease Control and Prevention, there were approximately 23,780 incidents of infectious mononucleosis (IM) between 2002 and 2018, with an ordinary prevalence rate of 104.2 cases per 100,000 person-years. The incidence of IM diagnoses became highest in many of the youngest age agencies and reduced with age. It happened to be so. White non-Hispanic service members had higher IM diagnoses (per 100,000 years) compared to other racial/ethnic groups, with IM diagnoses among recruits being other classified employees 3.4 times the name (106 per 100,000 years ) and policing 5.6 times (64.7 per 100,000 p-years) The increased incidence of infectious (IM) nuclear mononuclear disease leads to a higher demand for diagnosis, leading to an increase.
Since mononucleosis is most common in teens and adults, an increasing number of adolescents worldwide is also a major driver of the market's growth. Asia is home to more than half of the world's adolescent population. More adolescents live in South Asia than any other region—nearly 350 million. With more than 300 million, East Asia and the Pacific come in second. Any of these regions has a much larger teenage population than any other place in the world. World Health Organisation (WHO) research estimates that there are approximately 1.2 billion adolescents (10–19 years old) around the world. Adolescents account for 25% of the population in some countries, and this percentage is expected to increase through 2050, mostly in low- and middle-income countries (LMICs), where close to 90% of 10- to 19-year-olds live. As a result, it is anticipated that throughout the projection period, demand for the Mononucleosis Diagnostic Market will increase due to rising incidences of infectious mononucleosis (IM) and the Increasing adolescent population. Thus, driving the Mononucleosis Diagnostic Market revenue.
The Mononucleosis Diagnostic Market segmentation, based on Test Type, includes Epstein Barr Virus (EBV) Antibody Test, Monospot Test, and Complete Blood Count Test. The monospot test segment dominated the market, accounting for 58% of market revenue. As revealed by a study published in the Clinical Journal of Sports Medicine in November 2021, in its mono spot test, the test had a sensitivity and specificity of 80% and 91%, respectively, and the resistance tests had sensitivities of 47-83%. A large connective shows the levels of transaminases and acute infectious mononucleosis, which may be used to diagnose the disease. The most dependable way to diagnose IM is the presence of a positive mono spot in the mononucleosis test. Consequently, the careful placing of high sensitivity and specificity is believed to provide the necessary drive for the further development of this field in the next few years. Even though mature people with Epstein-Barr virus as the first infection of the mononucleosis disease group can hardly be found, infectious mononucleosis is mostly recognized with overnight fever and sore throat for adults. Since these diseases are more prevalent among young peers, they are expected to be the ones to drive the market.
Figure 1: Mononucleosis Diagnostic Market, by Test Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Mononucleosis Diagnostic Market segmentation, based on the End-User, includes Hospitals, Laboratories, and Others. The Hospitals segment dominated the market, accounting for 58% of market revenue. Hospitals are also well-equipped with diagnostic facilities that are almost painlessly equipped, like lab work and other crucial tests for NV that are needed in the diagnosis of mononucleosis. Facilities like this help physicians perform precise and timely diagnoses, which is thereby responsible for the growth of this market segment.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Mononucleosis Diagnostic market in North America can be attributed to several key factors. More promising factors are the relatively well-developed healthcare infrastructure and high adoption of advanced diagnosis techniques, which are the region's key points to higher growth. U.S. healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.3 percent. This region segment`s mononucleosis diagnostic market is being driven by two major factors: the rising need for immediate and accurate diagnosis, including the high public uptake of the necessity for fast diagnosis and treatment.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: MONONUCLEOSIS DIAGNOSTIC MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Mononucleosis Diagnostic Market accounts for the second-largest market share. One virus in particular that causes mononucleosis, the most popular disease known as "the kissing disease" or "mono," is called Epstein-Barr Virus (EBV). In 2022, the number of infectious mononucleosis cases in Spain amounted to nearly 26,400, up from 18,700 cases reported a year earlier. The highest number of mononucleosis cases in the European country was registered in 2016, after reaching approximately 46,300 thousand infections. This influenza virus has increased in prevalence across Europe, causing more and more demand for diagnostic tests. Further, the German Mononucleosis Diagnostic Market held the largest market share, and the UK Mononucleosis Diagnostic Market was the fastest-growing market in the European region.
The Asia-Pacific Mononucleosis Diagnostic Market is expected to grow at the fastest CAGR from 2024 to 2032. As per the United Nations Children's Fund, almost 25% of all teens worldwide, or 329 million adolescents, will reside in the East Asia and Pacific region as of January 2022. The substantial number of young people suggests that there is a considerable need for diagnostic testing for mononucleosis. Furthermore, according to a November 2022 Verywell Health article, between 25% and 50% of American children from poorer socioeconomic classes would have had EBV by the time they were 4 years old. Furthermore, following an EBV infection, 75% of young adults will receive a mono diagnosis. Throughout the projection period, the rising cases of mononucleosis and EBV in the region are expected to drive market growth. Moreover, China’s Mononucleosis Diagnostic Market held the largest market share, and the Indian Mononucleosis Diagnostic Market was the fastest-growing market in the Asia-Pacific region.
Mononucleosis Diagnostic Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Mononucleosis Diagnostic market grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Mononucleosis Diagnostic industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Mononucleosis Diagnostic industry to benefit clients and increase the market sector. In recent years, the Mononucleosis Diagnostic industry has offered some of the most significant advantages to the medical field. Major players in the Mononucleosis Diagnostic Market, including Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Weizmann Institute of Science (Israel), Biotest AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Genzyme (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), BD (U.S.), DiaSorin Molecular LLC (U.S.) are attempting to increase market demand by investing in research and development operations.
Abbott discovers, manufactures, and distributes a wide range of healthcare products, such as adult and pediatric nutritional items, branded generic medications, and diagnostic equipment and tests. Heart failure, electrophysiology, rhythm management, vascular and structural heart devices, and neuromodulation devices are among the medical products that the company also sells. The company offers dietary supplements, nutrition products, and minerals. It operates manufacturing plants all around the world and maintains research and development centers in the US, Colombia, India, Singapore, Spain, and the UK. The company markets its products across Europe, Asia-Pacific, Africa, Latin America, the Middle East, and North America. The US headquarters of Abbott is located in Abbott Park, Illinois. In 2021, Abbott Laboratories purchased Walk Vascular, LLC, a medical device company specializing in the development of minimally invasive devices for vascular disease, to expand its portfolio in the vascular sector.
A holding company, Daiichi Sankyo Co Ltd, is responsible for pharmaceutical product development, manufacturing, and marketing. The company provides a broad range of over-the-counter (OTC), prescription, and vaccination drugs. Its product line includes medications for cancers of all kinds as well as conditions including diabetes, metabolic, neurological, nephrological, cardiovascular, and infectious disorders. The company also conducts research on immunological disorders and uncommon diseases in addition to cancer. Through its group companies and an extensive network of medical professionals, Daiichi Sankyo promotes its products. It operates in Europe, Asia, South and Central America, and North America. Tokyo, Japan, is home to Daiichi Sankyo's headquarters.
Key companies in the Mononucleosis Diagnostic Market include.
Mononucleosis Diagnostic Industry Developments
October 2022: To determine the T-cell immune response specific to the Epstein-Barr virus, Eurofins Viracor launched a functional T-cell test. The test has become part of Viracor's innovative inSIGHT diagnostic portfolio of virus-specific cell-mediated immunity tests.
May 2022: Hologic, Inc. expanded its transplant pathogen monitoring menu on the Panther Fusion system with the CE marking of two additional molecular tests, the Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay. The assays assess the EBV virus's viral load and aim to aid in the identification and management of patients undergoing solid organ transplantation as well as those undergoing hematopoietic stem cell transplant.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.7 Billion |
| Market Size 2024 | USD 1.8 Billion |
| Market Size 2032 | USD 3.28 Billion |
| Compound Annual Growth Rate (CAGR) | 8.60% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Test Type and End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Weizmann Institute of Science (Israel), Biotest AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Genzyme (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), BD (U.S.), DiaSorin Molecular LLC (U.S.). |
| Key Market Opportunities | · Technological advancements in diagnostic testing methods for mononucleosis |
| Key Market Dynamics | · The rising prevalence of infectious mononucleosis is driving expansion. |
Frequently Asked Questions (FAQ) :
The Mononucleosis Diagnostic Market size was valued at USD 1.7 Billion in 2023.
The Mononucleosis Diagnostic Market is projected to grow at a CAGR of 8.60% during the forecast period, 2024-2032.
North America had the largest share of the market.
The key players in the market are Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Weizmann Institute of Science (Israel), Biotest AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Genzyme (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), BD (U.S.), DiaSorin Molecular LLC (U.S.)
The Monospot Test segment dominated the market in 2023.
The Hospitals segment had the largest share of the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
